Article

Study Urges Lung Cancer Trials to Include Survivors

The study, published in the Journal of the National Cancer Institute, found that having a prior cancer diagnosis did not affect outcomes among the patients with advanced lung cancer, which means these patients should be allowed to take part in clinical trials of new lung cancer treatments.

Cancer survivors should not be excluded from clinical trials of new lung cancer treatments, according to a study that challenges common practice.

Researchers analyzed data from nearly 103,000 people older than 65 who were diagnosed with advanced lung cancer between 1992 and 2009. Of those patients, nearly 15% had survived previous cancers, including prostate, breast and gastrointestinal cancers.

Those who had survived an earlier cancer had 10% better overall survival and 20% better lung cancer-specific survival than those who had never been diagnosed with another cancer before getting lung cancer.

Link to the complete report on Medline Plus: http://1.usa.gov/1EJzIEO

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos
Coral Omene, MD, PhD, sitting for a vieo interview
Constance Blunt, MD, medical oncologist, Mary Bird Perkins Cancer Center
Coral Omene, MD, PhD, sitting for a vieo interview
David Awad, PharmD, BCOP
Screenshot of Coral Omene, MD, PhD
ASCO 2025
Constance Blunt, MD, medical oncologist, Mary Bird Perkins Cancer Center
Cathy Eng, MD, FACP, FASCO
Nini Wu, MD, Navista
Eileen Peng, PharmD, sitting for a video interview
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo